2021³âµµ ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãá°èÇмú´ëȸ : 2021-04-02±³À°ÀÏÀÚ : 2021-04-02
±³À°Àå¼Ò : ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ ¹× ´ëȸÀǽÇ
±³À°ÁÖÁ¦ :
2021³âµµ ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãá°èÇмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ
´ã´çÀÚ : À̼¼Àº
¿¬¶ôó : 02-784-2742
À̸ÞÀÏ :
secretariat@kcnp.or.kr ±³À°Á¾·ù : Á¤½Å°Ç°ÀÇÇаú
Âü¼®¿¹»óÀοø : 120¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 13 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í »çÀüµî·Ïºñ Æò»ýȸ¿ø:¸éÁ¦/Á¤È¸¿ø:50,000/ºñȸ¿ø:60,000/ÁØȸ¿ø¹×±âŸ:30,000 ´çÀϵî·Ïºñ Æò»ýȸ¿ø:10,000/Á¤È¸¿ø:60,000/ºñȸ¿ø:80,000/ÁØȸ¿ø¹×±âŸ:40,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04¿ù 02ÀÏ ÄÁº¥¼ÇȦ 09:30~09:55 Pharmacogenomics and child and adolescent psychiatry ¾çÂù¸ð(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ ÄÁº¥¼ÇȦ 09:55~10:20 Pharmacogenomics and schizophrenia À̽ÂÀç(°æºÏÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ ÄÁº¥¼ÇȦ 10:20~10:40 Pharmacogenomics and mood disorder °ÇÑ°íÀººñ(±¹¸³³ªÁÖº´¿ø)
±³À°½Ã°£ 04¿ù 02ÀÏ ´ëȸÀÇ½Ç 09:30~09:55 Big data in depression °¿ø¼·(°æÈñÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ ´ëȸÀÇ½Ç 09:55~10:20 Big data in bipolar disorder ±è°æ¹Î(±¹¸³³ªÁÖº´¿ø)
±³À°½Ã°£ 04¿ù 02ÀÏ ´ëȸÀÇ½Ç 10:20~10:40 Big data in schizophrenia ÀÌÁß¼±(¿ï»êÀÇ´ë)
ÈÞ½Ä 04¿ù 02ÀÏ 10:40~10:55 ()
±³À°½Ã°£ 04¿ù 02ÀÏ ÄÁº¥¼ÇȦ 10:55~11:20 Treatment-resistant depression ¹Ú¼º¿ë(°è¿äº´¿ø)
±³À°½Ã°£ 04¿ù 02ÀÏ ÄÁº¥¼ÇȦ 11:20~11:45 Treatment-resistant bipolar disorder ÀÓÀº¼º(½Å¼¼°èÈ¿º´¿ø)
±³À°½Ã°£ 04¿ù 02ÀÏ ÄÁº¥¼ÇȦ 11:45~12:05 Treatment-resistant schizophrenia ÀÌÁ¤¼®(±¹¹Î°Ç°º¸ÇèÀϻ꺴¿ø)
±³À°½Ã°£ 04¿ù 02ÀÏ ´ëȸÀÇ½Ç 10:55~11:20 5-HT2C ¹®Àº¼ö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ ´ëȸÀÇ½Ç 11:20~11:45 5-HT3 Á¤¸íÈÆ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ ´ëȸÀÇ½Ç 11:45~12:05 5-HT7 ¹Ú¿µ¹Î(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ ÄÁº¥¼ÇȦ 12:05~12:35 Positive affects, Is it predicts remission? Àå½ÂÈ£(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ ÄÁº¥¼ÇȦ 12:35~13:05 Benefits of Agomelatine treatment strategy ¼Á¤¼®(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ ´ëȸÀÇ½Ç 12:05~12:35 Esketamine clinical trial review for TRD/MDSI ¿Õ¼º¹Î(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ ´ëȸÀÇ½Ç 12:35~13:05 Building best clinical practice for TRD by SPRAVATO therapy ¼Û¹Î±Ô(¼º¸ð°ø°¨Á¤½Å°Ç°ÀÇÇаúÀÇ¿ø)
ÈÞ½Ä 04¿ù 02ÀÏ 13:05~13:20 ()
±³À°½Ã°£ 04¿ù 02ÀÏ ÄÁº¥¼ÇȦ 13:20~13:45 Monotherapy vs combination therapy ½É¼¼ÈÆ(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ ÄÁº¥¼ÇȦ 13:45~14:05 Duration of maintenance and therapeutic goal ¼ºÇü¸ð(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ ÄÁº¥¼ÇȦ 14:05~14:30 Adverse effect of pharmacotherapy and management À̹®¼ö(°í·ÁÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ ´ëȸÀÇ½Ç 13:20~13:45 DTx, What is it? Á¶Ã¶Çö(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ ´ëȸÀÇ½Ç 13:45~14:05 DTx in mood disorder ÀÌÇåÁ¤(°í·ÁÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ ´ëȸÀÇ½Ç 14:05~14:30 DTx in ADHD and insomnia ±è¼öÁø(AIMMED)
±³À°½Ã°£ 04¿ù 02ÀÏ ÄÁº¥¼ÇȦ 14:30~14:50 Melatonin and Agomelatine ±è¼±¹Ì(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ ÄÁº¥¼ÇȦ 14:50~15:10 Zopiclone and Zolpidem ±è¿øÇü(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ ÄÁº¥¼ÇȦ 15:10~15:40 Aripiprazole LAI(Maintena¢ç) and Aripiprazole Lauroxil LAI(Aristada¢ç) ÀÌ°¼ö(Â÷ÀÇ°úÇдë)
±³À°½Ã°£ 04¿ù 02ÀÏ ´ëȸÀÇ½Ç 14:30~15:05 Importance of multifactorial condition management ¾çÁ¾Ã¶(ÀüºÏÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ ´ëȸÀÇ½Ç 15:05~15:40 Successful management of patient adherence ±è¿ø(ÀÎÁ¦ÀÇ´ë)
ÈÞ½Ä 04¿ù 02ÀÏ 15:40~15:50 ()
±³À°½Ã°£ 04¿ù 02ÀÏ ÄÁº¥¼ÇȦ 15:50~16:10 Mode of administration(oral, transdermal, IV) and analgesic effect ±èÀå·¡(±¹¸³ÀÇ·á¿ø)
±³À°½Ã°£ 04¿ù 02ÀÏ ÄÁº¥¼ÇȦ 16:10~16:30 Current drugs for pain in clinical guidelines Á¤Á¶Àº(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ ÄÁº¥¼ÇȦ 16:30~17:00 Practice of opioid prescription È«Á¤¿Ï(Àͻ꺴¿ø)
±³À°½Ã°£ 04¿ù 02ÀÏ ´ëȸÀÇ½Ç 15:50~16:10 Loxapine inhalation(Adasuve¢ç) ±èÅÂÈñ(¿¬¼¼¿øÁÖÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ ´ëȸÀÇ½Ç 16:10~16:30 Aripiprazole buccoadhesive film(Depipzo¢ç) Á¤¿µÀº(Á¦ÁÖÀÇ´ë)
±³À°½Ã°£ 04¿ù 02ÀÏ ´ëȸÀÇ½Ç 16:30~17:00 Buprenorphine/Naloxone sublingual tablet/film(Zubsolv¢ç/Suboxone¢ç) ³ªÀÇÇö(¿¹¼öº´¿ø)